Epigen Biosciences (San Diego, USA), a start-up pharmaceutical company, entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease and other chronic diseases associated with metabolic syndrome.
EPGN696 is an orally available, selective LPA1 receptor antagonist. In preclinical testing, EPGN696 demonstrated efficacy and safety in rodent models of kidney disease by targeting fibrosis, inflammation and growth factor responses.
Under the terms of the agreement, Epigen will receive upfront and potential milestone payments upon the achievement of specific development goals up to $200 million. In addition, Epigen also will be eligible to receive tiered royalties and milestones on the worldwide sales of products that arise from the collaboration.
The two companies will collaborate on the development of EPGN696 for diabetic kidney disease (DKD) and other indications.